Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial
Steven G Kelsen, Ioana O Agache, Weily Soong, Elliot Israel, Geoffrey L Chupp, Dorothy S Cheung, Wiebke Theess, Xiaoying Yang, Tracy L Staton, David F Choy, Alice Fong, Ajit Dash, Michael Dolton, Rajita Pappu, Christopher E Brightling, Steven G Kelsen, Ioana O Agache, Weily Soong, Elliot Israel, Geoffrey L Chupp, Dorothy S Cheung, Wiebke Theess, Xiaoying Yang, Tracy L Staton, David F Choy, Alice Fong, Ajit Dash, Michael Dolton, Rajita Pappu, Christopher E Brightling
Abstract
Background: The IL-33/ST2 pathway is linked with asthma susceptibility. Inhaled allergens, pollutants, and respiratory viruses, which trigger asthma exacerbations, induce release of IL-33, an epithelial-derived "alarmin." Astegolimab, a human IgG2 mAb, selectively inhibits the IL-33 receptor, ST2. Approved biologic therapies for severe asthma mainly benefit patients with elevated blood eosinophils (type 2-high), but limited options are available for patients with low blood eosinophils (type 2-low). Inhibiting IL-33 signaling may target pathogenic pathways in a wider spectrum of asthmatics.
Objectives: This study evaluated astegolimab efficacy and safety in patients with severe asthma.
Methods: This double-blind, placebo-controlled, dose-ranging study (ZENYATTA [A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma]) randomized 502 adults with severe asthma to subcutaneous placebo or 70-mg, 210-mg, or 490-mg doses of astegolimab every 4 weeks. The primary endpoint was the annualized asthma exacerbation rate (AER) at week 54. Enrollment caps ensured ∼30 patients who were eosinophil-high (≥300 cells/μL) and ∼95 patients who were eosinophil-low (<300 cells/μL) per arm.
Results: Overall, adjusted AER reductions relative to placebo were 43% (P = .005), 22% (P = .18), and 37% (P = .01) for 490-mg, 210-mg, and 70-mg doses of astegolimab, respectively. Adjusted AER reductions for patients who were eosinophil-low were comparable to reductions in the overall population: 54% (P = .002), 14% (P = .48), and 35% (P = .05) for 490-mg, 210-mg, and 70-mg doses of astegolimab. Adverse events were similar in astegolimab- and placebo-treated groups.
Conclusions: Astegolimab reduced AER in a broad population of patients, including those who were eosinophil-low, with inadequately controlled, severe asthma. Astegolimab was safe and well tolerated.
Trial registration: ClinicalTrials.gov NCT02918019.
Keywords: IL-33; ST2; asthma exacerbations; eosinophils; severe asthma.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed